2026 Q2 - tulosraportti
58 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 256 | ||
| 11 804 | ||
| 6 171 | ||
| 3 138 | ||
| 2 175 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenTI Bob le plast I think it is completely fine that people think Circio is both overpriced and identical to all other biotech, and as the former eminent biotech analyst C.J. Hambro once said: ...every representative in this forum must have the opportunity to express the confusion that reigns in his mind. All specific data presented so far is of course important (heart, AAV, LNP, 200x increased protein expression vs mRNA etc.), but strictly speaking, that is not the most important thing. The most important thing is that the data makes it probable that Circio has now established a gene therapy platform that plugs all the holes from the rough and inaccurate 1st generation gene therapy. This technology operates at such a fundamental level inside the cell (DNA=>RNA=>Protein) that pre-clinical data will largely be able to say something about further functionality. All other biotechs on OSE have operated at a much higher level of complexity, e.g. directing an immune response specifically against a specific cancer indication. There has never been a biotech company in a corresponding position before with so many potential angles, legs to stand on, and so many shots on goal as Circio. Nor has it had a position so far forward in the front pack on something that inevitably is coming to be a dominant area within biotech/pharma. If one is to summarize the comparison against other companies (nano, ulti, bgbio, trvx, pcib etc.), the common denominator for all of these is that they were narrow niche companies. And then with a technology that already towards the end of 2026 can be said to be approaching outdated. Thus companies that only have one leg to stand on and that depend on a binary outcome for the way forward. And where statistically there is over a 90% probability that they fail. Not least because they operated in hyper-competitive indications. It is a long way off before Circio needs to worry about such trivialities, primarily because the value of the company/technologies will not be driven by the outcome of clinical studies. Against that backdrop, I personally just get a bit exasperated that the value and potential of Circio at all times is to be compared with anything that has had a hint of a pulse within the biotech sector on OSE. That is strictly speaking comparing an apple to a hippopotamus.
·2 t sitten · MuokattuEli Lilly with giant results in Q3 as well. They are looking for early-stage companies with extraordinary technology. Lilly is my tip for the Big Pharma collaboration, possibly in Alzheimer's. They recently shut down another study in that disease. Something better on the way???😊 “We’re just solving for great products, great science and great people that we can bring into the company and fuel growth into the decades to come,” The staggering revenue growth has left Lilly with plenty of cash to play with for deals. “Some of that is very early-stage deal making, which oftentimes are not really even press released by us, so some of them maybe you don’t know as much about,” he said. https://www.biospace.com/business/lillys-guidance-has-jumped-by-10b-as-glp-1-sales-keep-blowing-past-expectations https://www.fiercebiotech.com/biotech/lilly-scraps-ph-2-alzheimers-disease-drug-it-did-not-meet-high-internal-bar 15. September they bought delivery technology for CNS. qurcan.com
Could it be that Eli og Lilly are coming to Circio's Halloween party in Oslo and are looking for the best drug on the market that they are willing to pay very well for...🤗
·3 t sittenNot in doubt that this is going to blow the bank. I then hope that it stays a bit quiet and calm in 2026. It is going to hurt a bit if one is forced to sell off a little bit, so one has the means to pay the return on their aks account. What is happening right now in this stock is nothing other than trading. sometimes you have to close your eyes, not think about money and then see where they have moved to. Tomorrow there is not going to be a news story about us shutting down and turning off the lights, after having expanded and hired a special female person.- ·3 t sitten · MuokattuA comfort for the impatient. There is a race going on in the world of circular rna. Circio therefore has at least as little time to move forward quickly in the process as some shareholders here, so as not to lose the race. Clear that they have been noticed at esgct26 https://www.bioworld.com/articles/735036-esgct-2026-beyond-viruses-for-nucleic-acid-delivery?v=preview https://lnkd.in/p/eVQmFF9N
It is being talked about that biotech will become the big investors' next haven....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
58 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenTI Bob le plast I think it is completely fine that people think Circio is both overpriced and identical to all other biotech, and as the former eminent biotech analyst C.J. Hambro once said: ...every representative in this forum must have the opportunity to express the confusion that reigns in his mind. All specific data presented so far is of course important (heart, AAV, LNP, 200x increased protein expression vs mRNA etc.), but strictly speaking, that is not the most important thing. The most important thing is that the data makes it probable that Circio has now established a gene therapy platform that plugs all the holes from the rough and inaccurate 1st generation gene therapy. This technology operates at such a fundamental level inside the cell (DNA=>RNA=>Protein) that pre-clinical data will largely be able to say something about further functionality. All other biotechs on OSE have operated at a much higher level of complexity, e.g. directing an immune response specifically against a specific cancer indication. There has never been a biotech company in a corresponding position before with so many potential angles, legs to stand on, and so many shots on goal as Circio. Nor has it had a position so far forward in the front pack on something that inevitably is coming to be a dominant area within biotech/pharma. If one is to summarize the comparison against other companies (nano, ulti, bgbio, trvx, pcib etc.), the common denominator for all of these is that they were narrow niche companies. And then with a technology that already towards the end of 2026 can be said to be approaching outdated. Thus companies that only have one leg to stand on and that depend on a binary outcome for the way forward. And where statistically there is over a 90% probability that they fail. Not least because they operated in hyper-competitive indications. It is a long way off before Circio needs to worry about such trivialities, primarily because the value of the company/technologies will not be driven by the outcome of clinical studies. Against that backdrop, I personally just get a bit exasperated that the value and potential of Circio at all times is to be compared with anything that has had a hint of a pulse within the biotech sector on OSE. That is strictly speaking comparing an apple to a hippopotamus.
- ·2 t sitten · MuokattuEli Lilly with giant results in Q3 as well. They are looking for early-stage companies with extraordinary technology. Lilly is my tip for the Big Pharma collaboration, possibly in Alzheimer's. They recently shut down another study in that disease. Something better on the way???😊 “We’re just solving for great products, great science and great people that we can bring into the company and fuel growth into the decades to come,” The staggering revenue growth has left Lilly with plenty of cash to play with for deals. “Some of that is very early-stage deal making, which oftentimes are not really even press released by us, so some of them maybe you don’t know as much about,” he said. https://www.biospace.com/business/lillys-guidance-has-jumped-by-10b-as-glp-1-sales-keep-blowing-past-expectations https://www.fiercebiotech.com/biotech/lilly-scraps-ph-2-alzheimers-disease-drug-it-did-not-meet-high-internal-bar 15. September they bought delivery technology for CNS. qurcan.comCould it be that Eli og Lilly are coming to Circio's Halloween party in Oslo and are looking for the best drug on the market that they are willing to pay very well for...🤗
- ·3 t sittenNot in doubt that this is going to blow the bank. I then hope that it stays a bit quiet and calm in 2026. It is going to hurt a bit if one is forced to sell off a little bit, so one has the means to pay the return on their aks account. What is happening right now in this stock is nothing other than trading. sometimes you have to close your eyes, not think about money and then see where they have moved to. Tomorrow there is not going to be a news story about us shutting down and turning off the lights, after having expanded and hired a special female person.
- ·3 t sitten · MuokattuA comfort for the impatient. There is a race going on in the world of circular rna. Circio therefore has at least as little time to move forward quickly in the process as some shareholders here, so as not to lose the race. Clear that they have been noticed at esgct26 https://www.bioworld.com/articles/735036-esgct-2026-beyond-viruses-for-nucleic-acid-delivery?v=preview https://lnkd.in/p/eVQmFF9NIt is being talked about that biotech will become the big investors' next haven....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 256 | ||
| 11 804 | ||
| 6 171 | ||
| 3 138 | ||
| 2 175 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
58 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenTI Bob le plast I think it is completely fine that people think Circio is both overpriced and identical to all other biotech, and as the former eminent biotech analyst C.J. Hambro once said: ...every representative in this forum must have the opportunity to express the confusion that reigns in his mind. All specific data presented so far is of course important (heart, AAV, LNP, 200x increased protein expression vs mRNA etc.), but strictly speaking, that is not the most important thing. The most important thing is that the data makes it probable that Circio has now established a gene therapy platform that plugs all the holes from the rough and inaccurate 1st generation gene therapy. This technology operates at such a fundamental level inside the cell (DNA=>RNA=>Protein) that pre-clinical data will largely be able to say something about further functionality. All other biotechs on OSE have operated at a much higher level of complexity, e.g. directing an immune response specifically against a specific cancer indication. There has never been a biotech company in a corresponding position before with so many potential angles, legs to stand on, and so many shots on goal as Circio. Nor has it had a position so far forward in the front pack on something that inevitably is coming to be a dominant area within biotech/pharma. If one is to summarize the comparison against other companies (nano, ulti, bgbio, trvx, pcib etc.), the common denominator for all of these is that they were narrow niche companies. And then with a technology that already towards the end of 2026 can be said to be approaching outdated. Thus companies that only have one leg to stand on and that depend on a binary outcome for the way forward. And where statistically there is over a 90% probability that they fail. Not least because they operated in hyper-competitive indications. It is a long way off before Circio needs to worry about such trivialities, primarily because the value of the company/technologies will not be driven by the outcome of clinical studies. Against that backdrop, I personally just get a bit exasperated that the value and potential of Circio at all times is to be compared with anything that has had a hint of a pulse within the biotech sector on OSE. That is strictly speaking comparing an apple to a hippopotamus.
- ·2 t sitten · MuokattuEli Lilly with giant results in Q3 as well. They are looking for early-stage companies with extraordinary technology. Lilly is my tip for the Big Pharma collaboration, possibly in Alzheimer's. They recently shut down another study in that disease. Something better on the way???😊 “We’re just solving for great products, great science and great people that we can bring into the company and fuel growth into the decades to come,” The staggering revenue growth has left Lilly with plenty of cash to play with for deals. “Some of that is very early-stage deal making, which oftentimes are not really even press released by us, so some of them maybe you don’t know as much about,” he said. https://www.biospace.com/business/lillys-guidance-has-jumped-by-10b-as-glp-1-sales-keep-blowing-past-expectations https://www.fiercebiotech.com/biotech/lilly-scraps-ph-2-alzheimers-disease-drug-it-did-not-meet-high-internal-bar 15. September they bought delivery technology for CNS. qurcan.comCould it be that Eli og Lilly are coming to Circio's Halloween party in Oslo and are looking for the best drug on the market that they are willing to pay very well for...🤗
- ·3 t sittenNot in doubt that this is going to blow the bank. I then hope that it stays a bit quiet and calm in 2026. It is going to hurt a bit if one is forced to sell off a little bit, so one has the means to pay the return on their aks account. What is happening right now in this stock is nothing other than trading. sometimes you have to close your eyes, not think about money and then see where they have moved to. Tomorrow there is not going to be a news story about us shutting down and turning off the lights, after having expanded and hired a special female person.
- ·3 t sitten · MuokattuA comfort for the impatient. There is a race going on in the world of circular rna. Circio therefore has at least as little time to move forward quickly in the process as some shareholders here, so as not to lose the race. Clear that they have been noticed at esgct26 https://www.bioworld.com/articles/735036-esgct-2026-beyond-viruses-for-nucleic-acid-delivery?v=preview https://lnkd.in/p/eVQmFF9NIt is being talked about that biotech will become the big investors' next haven....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 256 | ||
| 11 804 | ||
| 6 171 | ||
| 3 138 | ||
| 2 175 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt